Meet
Luke Frazier

He/him
Consultant I

Luke Frazier supports a range of clients with evidence-based research and analysis on healthcare policy developments.

He applies his background in healthcare public policy and public affairs advising clients on the impact of policy to industry, with a particular focus on global vaccine policy and access along with policy issues in Medicare Part B.

Prior to joining Avalere, Luke held a variety of internship positions, including an apprenticeship with Schmidt Public Affairs, where he drafted healthcare issue briefs and opinion editorials that were placed in major national publications and crafted messaging strategies for client campaigns. Additionally, he interned in the offices of Senator Tina Smith and Governor Mark Dayton, where he worked on health policy and briefed staff on relevant issues.

Luke has a BA in international affairs from the George Washington University.

Authored Content

June 21, 2024 | Insights & Analysis > Drug Pricing and Affordability

White Paper: Infusion Care and White-Bagging Requirements
Avalere surveyed providers on the administrative and economic costs of white-bagging requirements on infusion centers.
June 12, 2024 | Insights & Analysis > Coverage and Payment

Patterns in Patient Access to MS Drugs
Avalere analysis finds that less clinically efficacious MS drugs have better coverage, more advantageous tiering, and lower UM compared to more efficacious drugs.
May 24, 2024 | Insights & Analysis > Coverage and Payment

MA Plans Increase Use of Step Therapy for Part B Drugs
In 2023, 54% of Medicare Advantage enrollees were in plans that required step therapy for 10 commonly used rheumatoid arthritis drugs covered under Part B.
April 22, 2024 | Insights & Analysis > Federal and State Policy

CMS’s Interpretation of “Qualifying Single-Source Drugs” in Medicare Negotiation
CMS’s definition of a “qualifying single-source drug” in the Medicare Drug Price Negotiation Program may impact manufacturers’ investment strategies.
April 2, 2024 | Insights & Analysis > Federal and State Policy

Research Explores Health Plan Perceptions of PDABs and UPLs
Avalere assessed how health plans may view UPLs, including implementation considerations and impacts on providers and patients (e.g., plan benefit design).
September 8, 2023 | Insights & Analysis > Drug Pricing and Affordability

Will Part D Redesign Lower OOP Costs for HIV Care?
The IRA’s Part D redesign could lower out-of-pocket costs for people with HIV; providers can help make sure their patients are aware of these changes.
October 5, 2022 | Videos > Vaccines and Public Health

Video: RSV Prevention, Part II: Pediatric Vaccines and Maternal immunization
Tune into the second episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss RSV prevention products currently in development, specifically maternal immunizations and pediatric vaccines.
October 5, 2022 | Interviews > Vaccines and Public Health

Podcast: RSV Prevention, Part II: Pediatric Vaccines and Maternal immunization
Tune into the second episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss RSV prevention products currently in development, specifically maternal immunizations and pediatric vaccines.
August 25, 2022 | Insights & Analysis > Federal and State Policy

Analysis of CMMI Models Projects Costs Rather than Savings
Avalere estimates that the CMMI will produce net costs of approximately $9.4 billion through 2026, in contrast to the CBO’s projected net savings of $34 billion.
July 30, 2022 | Insights & Analysis > Vaccines and Public Health

Comparing Medicare FFS Pneumococcal Vaccination Rates in 2019 and 2020
A new study from Avalere analyzes age, race and ethnicity, and Medicare-Medicaid dual-eligibility status of Medicare Fee-For-Service (FFS) beneficiaries with pneumococcal vaccine claims in 2019 and 2020.
April 6, 2022 | Insights & Analysis > Health Equity

Medicare Draft NCD for Alzheimer’s Drugs Poses Equity Questions
Avalere analysis seeks to understand potential access to clinical trial sites by race, given the draft requirement to ensure diverse participation.
March 11, 2022 | Insights & Analysis > Coverage and Payment

Medicare Draft Coverage for Alzheimer’s Drugs May Challenge Access
Thirty-one percent of rural Medicare fee-for-service beneficiaries with early-onset Alzheimer’s disease or a mild cognitive impairment diagnosis do not have access to a hospital outpatient department in their county, and fewer than 1% live near an Alzheimer’s disease research center.
November 18, 2021 | Insights & Analysis > Drug Pricing and Affordability

Part B Drug Negotiation Under BBBA Would Reduce Payments to Providers
New Avalere analysis finds that the latest version of Medicare negotiation in the Build Back Better Act (BBBA) would lead to a 40% cut on average for Medicare providers that furnish the Part B drugs that are likely to be initially targeted for negotiation.
August 18, 2021 | Insights & Analysis > Vaccines and Public Health

Vaccination Rates Among Medicaid Adolescents Declined During Pandemic
A new claims-based analysis from Avalere examined vaccine uptake among low-income adolescents enrolled in Medicaid Managed Care and found a 26% decline in routine vaccinations when comparing March–October 2019 to the same period in 2020.
January 21, 2021 | Insights & Analysis > Drug Pricing and Affordability

MFN Model Would Have Had a Major Impact on Certain Providers
New Avalere analysis finds that the the Most Favored Nation (MFN) Model would have a significant negative impact on Medicare providers that furnish Part B drugs—especially in oncology and rheumatology—and those in rural areas.
October 27, 2020 | Interviews > Vaccines and Public Health

Podcast: Designing Pull Funding for a COVID-19 Vaccine
Tune into another episode of Avalere’s Journal Club Review podcast series on Avalere Health Essential Voice. In this segment, our health policy experts discuss a recent study in which a simulation was used to determine whether pull funding could overcome issues related to speed, scaling, and pricing for a COVID-19 vaccine.
September 17, 2020 | Insights & Analysis > Drug Pricing and Affordability

“Most Favored Nation” EO Creates New Questions on International Prices
On September 13, the Trump Administration released the much-anticipated “Most Favored Nation” (MFN) Executive Order (EO), calling for models that would cap the price Medicare pays for select Part B and D drugs. The President’s EO underscores the administration’s continued focus on reducing prescription drug price disparities between the US and other developed countries.